Resverlogix has exceeded the enrolment target of more than 2,400 patients in its Phase III BETonMACE trial, evaluating the effect of its drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 Diabetes Mellitus (DM) and low high-density lipoproteins (HDL).

The pivotal trial enrolled its first patient in November 2015.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“Achieving full enrolment early leaves two major clinical reflection points that will transpire in 2018.”

Its primary endpoint is to establish a relative risk reduction (RRR) of major adverse cardiac events (MACE), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke.

Secondary pre-specified objectives of the trial include the analysis of renal function and MACE in patients with chronic kidney disease (CKD) stage three as well as cognition, measured by the Montreal Cognitive Assessment (MoCA) in all patients aged 70 and over.

Resverlogix president and CEO Donald McCaffrey said: “Achieving full enrolment early leaves two major clinical reflection points that will transpire in 2018.

“The first will be attaining 75% of our targeted 250 MACE events, being 188 events in total, thus allowing us the ability to conduct a sample size re-estimation analysis assuring that the trial will be sufficiently powered to confirm relative risk reduction.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“The second major reflection point will be the most important, the Primary Endpoint read-out around the end of 2018. This read-out will prove pivotal in planning our FDA and EMA registration applications.”

Resverlogix said it is exploring the option of enrolling patients in the US for the BETonMACE trial.

It also intends to explore the option of relying on existing BETonMACE data to file a US New Drug Application (NDA) for apabetalone.

Apabetalone (RVX-208) is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact